1. Scrip
  2. >>Business

Glenmark Readies Push For SGLT2i With Torrent Deal, More In Store

 
• By Anju Ghangurde

Glenmark is pressing ahead with plans to widen market opportunities for remogliflozin in India. Its co-marketing alliance with Torrent is potentially the first among similar deals anticipated for the novel sodium glucose co-transporter-2 (SGLT2) inhibitor in a competitive segment.

Diabetes
Glenmark has firmed up a deal with Torrent for remogliflozin

Glenmark Pharmaceuticals Ltd. has sealed a licensing deal with peer Torrent Pharmaceuticals Ltd. for its novel sodium glucose co-transporter-2 (SGLT2) inhibitor, remogliflozin etabonate, as it pursues rapid market expansion for the diabetes therapy in India.

This is potentially the first of such alliances as Glenmark seeks to shake up the SGLT2 inhibitor segment, emulating what it achieved with teneligliptin in the competitive Indian DPP-4 (dipeptidyl peptidase-4) inhibitor market. Glenmark launched the first version of Mitsubishi Tanabe Pharma Corp

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

In Brief: Sanofi Commits $20bn To US R&D And Manufacturing By 2030

 
• By Sushmita Panda

Move by French major aligns with broader industry efforts to localize production amid political pressure, as Trump pushes to onshore manufacturing and hints at easing tariff threats.

Eisai Forecasts 73% Leqembi Sales Rise In FY25 As Demand Expands

 
• By Mandy Jackson

Eisai spent most of its FY24 earnings call discussing plans for growing sales of Biogen-partnered Alzheimer’s drug Leqembi from JPY44.3bn ($304.1m) to JPY76.5bn ($525.1m) in FY25.

UK-India FTA Could Offer ‘Significant Benefits’ For Generics, Biosimilars

 
• By Dave Wallace

A free trade agreement between the UK and India could offer “significant benefits for the generic and biosimilar sectors,” Medicines UK believes. The off-patent industry association has also suggested further avenues for collaboration between the two governments.

Will Other Major MASH Deals Follow GSK/Boston Pharma?

 
• By Joseph Haas

GSK’s $1.2bn payout for Boston Pharma’s efimosfermin is the first billion-dollar-plus MASH deal in nearly nine years, but several other advanced MASH programs could be positioned for takeout.

More from Scrip

Will Other Major MASH Deals Follow GSK/Boston Pharma?

 
• By Joseph Haas

GSK’s $1.2bn payout for Boston Pharma’s efimosfermin is the first billion-dollar-plus MASH deal in nearly nine years, but several other advanced MASH programs could be positioned for takeout.

Merck’s Welireg Adrenal Tumor Rollout Targets Specialized Centers

 
• By Alaric DeArment

The drugmaker won US FDA approval for the HIF-2α inhibitor in pheochromocytoma and paraganglioma, a rare cancer of the adrenal glands, in adolescents and adults.

Most Favored Nation Policy ‘Lazy, Misguided,’ But US Price Reforms Politically ‘Inevitable’

 
• By Cathy Kelly

Policy experts and pharma executives react to President Trump’s executive order on “equalizing” drug prices between the US and comparable nations at the ISPOR 2025 conference.